Blinatumomab
Reading tools
Approved by the FDA on 3 December 2014, Blincyto is used for treatment-resistant B-Cell Acute Lymphoblastic Leukemia. This blood cancer is characterized by a marked increase in inactive B cells in the bone marrow. Blincyto captures cancer-fighting lymphocytes through CD19 and CD3.
It is the first drug approved with this mechanism of action. Difficulty breathing and low blood pressure are its most important side effects.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.